Mammo Responsibility Ups Screening; Opioids for Cancer Pain? Ignored Signs of CRC News, features, and commentary about cancer-related issues Dec 21, 2023
Can JAK Inhibition Help Overcome Lenalidomide Resistance in Myeloma? Early-phase experience with ruxolitinib suggests potential role in relapsed/refractory disease Dec 21, 2023 video
Homelessness Tied to Worse Cancer Outcomes Among Veterans However, all-cause mortality rates in lung, colon cancer lower versus other healthcare settings Dec 21, 2023
Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years Bispecific antibody also shows high response rates in frontline setting Dec 20, 2023 video
Positive Results for Odronextamab in Relapsed/Refractory DLBCL But experts aren't sure where it would fit in with currently approved bispecifics Dec 20, 2023 video
'Curable': A Case for Precision of Language Patients need a clear description of their prognosis Dec 19, 2023
Psilocybin May Help Ease Depression in Cancer Patients In small trial, half had early remission of depressive symptoms after psilocybin-assisted therapy Dec 18, 2023
National Database Study Finds Higher Risk for Barrettβs Esophagus in IBD But no greater chance of BE-tied malignancy for these patients Dec 16, 2023
The 'Before and After': An Eye Surgeon's Unexpected Finding There are a few possible diagnoses in patient with headaches, blurred vision, but one stands out Dec 16, 2023
FDA Approves New First-Line Standard of Care in Bladder Cancer Enfortumab vedotin plus pembrolizumab doubled survival as compared with chemotherapy Dec 15, 2023
JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma Phase II findings on golidocitinib will form the basis of an accelerated approval application Dec 15, 2023
Hematocrit Stabilized in Polycythemia Vera Treated With Novel Hepcidin Mimetic Rusfertide maintained hematocrit Dec 15, 2023
Atezolizumab Plus Carboplatin Boosts Survival in Metastatic TNBC But editorialists note that with recent advances, "it is hard to justify" use of combination Dec 15, 2023
FDA Approves Belzutifan for Advanced Renal Cell Carcinoma HIF-2 inhibitor indicated for patients who progress after immunotherapy and anti-VEGF Dec 15, 2023
Why Some Myeloma Patients Refuse Stem Cell Transplant Study shows the various factors behind refusal of autologous stem cell transplantation Dec 15, 2023 video
'Exploding' Field of Antibody-Drug Conjugates Makes Inroads in Ovarian Cancer Our panel of experts discuss the latest data from various ongoing trials Dec 14, 2023 video
Andre Braugher's Cancer Dx; Malignancies Rising in Younger Adults; Negative Trials News, features, and commentary about cancer-related issues Dec 14, 2023
FDA OKs Maintenance Option for High-Risk Neuroblastoma Eflornithine approved to reduce relapse risk in both kids and adults Dec 14, 2023
Ibrutinib-Venetoclax Improves PFS in R/R Mantle Cell Lymphoma Will results revive ibrutinib role in MCL following withdrawal of accelerated approval? Dec 13, 2023
'Half-Matched' BMTs Effective in Severe Sickle Cell Disease High survival rates observed in patients not normally suitable for transplant Dec 13, 2023
Lenvatinib-Pembrolizumab Combo Misses Goal in First-Line HCC Trial Numerical advantages in OS, PFS fall short of statistical significance Dec 13, 2023
Pomalidomide Cuts Severe Epistaxis in Genetic Bleeding Disorder 24 weeks of daily treatment significantly reduced recurrent nosebleeds in HHT trial Dec 13, 2023
Early Detection Is Key to Higher Cure Rates in Ovarian Cancer "We are not aware of precancer stages for ovarian cancer" Dec 13, 2023
Four Drugs Top Three for Upfront Treatment of Multiple Myeloma Adding anti-CD38 antibodies boosts response and PFS, but timing, sequencing, cost questioned Dec 13, 2023
One in Five BRCA-Positive Breast Cancer Patients Able to Conceive Disease-free survival comparable between patients who did and did not become pregnant Dec 12, 2023
Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia Investigational drug revumenib now under review at FDA for KMT2A-rearranged disease Dec 12, 2023
Novel Monoclonal Antibody Reduces Bleeds in Hemophilia A and B Marstacimab reduced the annualized bleeding rate versus on-demand, prophylactic treatments Dec 12, 2023
Ruxolitinib Combinations Reduce Spleen Volume in Myelofibrosis Combos with navitoclax or pelabresib led to more patients achieving reductions Dec 12, 2023
KEYNOTE-A18 Data Are 'Practice-Changing' for Cervical Cancer Domenica Lorusso details the importance of modern radiotherapy in this regimen Dec 12, 2023
Axatilimab Shows Efficacy in Recurrent/Refractory GVHD Highest overall response rate and least toxicity seen with lowest dose Dec 11, 2023
MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia No advantage for MRD-negative patients in first remission after induction, regardless of FLT3 ITD Dec 11, 2023
A Closer Look at the Approval of CRISPR/Cas9 Gene Therapy for Sickle Cell Disease This landmark event brings up broader considerations and implications for other diseases Dec 11, 2023
ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission Better 2-year PFS, OS, but not applicable to primary refractory disease Dec 10, 2023
Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients Time-limited approach based on MRD response outperforms FCR, but U.S. applicability unclear Dec 10, 2023
Emicizumab Safe, Effective, in Infants With Hemophilia A More than half of children in study had no treated bleeds at follow-up of more than 100 weeks Dec 10, 2023
Add-On Inavolisib Ups PFS in PIK3CA-Mutated Breast Cancer Triplet therapy may surpass benefits of current "pretty active doublet" therapy, expert says Dec 10, 2023
Lovo-Cel 'Life-Changing, Transformative' in Sickle Cell Disease Near complete resolution of pain events in patients, including adolescents Dec 10, 2023
Bispecific Antibody Combination Active in Metastatic HR+/HER2+ Breast Cancer Two-thirds of patients progression free at 6 months with zanidatamab, palbociclib, fulvestrant Dec 10, 2023
Grappling With Our Deadliest Cancer Here are essential steps to improve lung cancer screening Dec 10, 2023
Benefits of Myeloma Regimens in the Real World Fall Well Short of Trials Survival 75% worse compared with outcomes seen in registrational studies Dec 10, 2023
